Sugi Predict

Sugi Predict / Compounds / SCHEMBL30891479

SCHEMBL30891479

SCHEMBL30891479

O=C(CN(CC(=O)NCCCCCC(=O)N(CCO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)CCO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)CC(=O)N[C@@H](CCCCNC(=O)OCc1ccccc1)C(=O)NCCCCCC(=O)OCc1ccccc1)NCCCCCC(=O)N(CCO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O)CCO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O

nearest known ligand 0.51

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ SIRT2 Q8IXJ6 9/20 0.47
▸ PTGER4 P35408 3/20 0.46
▸ SIRT1 Q96EB6 7/20 0.43
▸ SIRT3 Q9NTG7 6/20 0.43
▸ CPB1 P15086 1/20 0.39
▸ CPB2 Q96IY4 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ TPSAB1 Q15661 1/20 0.39
▸ FOLH1 Q04609 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30891431 0.97 SIRT2 (0.50) SIRT2PTGER4SIRT1SIRT3MEN1
SCHEMBL29454921 0.94 SIRT2 (0.48) SIRT2PTGER4SIRT1SIRT3CPB1
SCHEMBL30891269 0.93 SIRT2 (0.42) SIRT2PTGER4SIRT1SIRT3MEN1
SCHEMBL29454919 0.91 SIRT2 (0.47) SIRT2PTGER4SIRT1SIRT3MEN1
SCHEMBL29454943 0.90 SIRT2 (0.49) SIRT2PTGER4SIRT1SIRT3CPB1
SCHEMBL29454928 0.90 SIRT2 (0.49) SIRT2PTGER4SIRT1SIRT3CPB1
SCHEMBL29454929 0.90 SIRT2 (0.49) SIRT2PTGER4SIRT1SIRT3CPB1
SCHEMBL30891318 0.90 MMP13 (0.40) SIRT2PTGER4FOLH1
SCHEMBL30661931 0.90 MMP13 (0.40) SIRT2PTGER4FOLH1
SCHEMBL30891356 0.90 LGALS8 (0.41) SIRT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260021190-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES MERCK SHARP & DOHME LLC (US) 2026-01-22 — — US disclosed
EP-4615487-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES Merck Sharp & Dohme LLC (US) 2025-09-17 — — EP disclosed
WO-2024102633-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES MERCK SHARP & DOHME LLC (US) 2024-05-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260021190-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES INSR, GPR119, GLP1R SIRT2 836/4885PTGER4 2324/4885SIRT1 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback